Xilio Therapeutics Files Q2 2024 10-Q
Ticker: XLO · Form: 10-Q · Filed: Aug 8, 2024 · CIK: 1840233
Sentiment: neutral
Topics: 10-Q, financials, biotech
Related Tickers: XLO
TL;DR
Xilio Therapeutics filed its Q2 10-Q. Financials and business updates inside.
AI Summary
Xilio Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business activities. Specific financial figures and operational details are available within the full filing.
Why It Matters
This filing provides investors with the latest financial health and operational status of Xilio Therapeutics, crucial for understanding its current trajectory and future prospects.
Risk Assessment
Risk Level: medium — As a clinical-stage biotechnology company, Xilio Therapeutics faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Filer of the 10-Q
- 20240630 (date) — Period of report
- 20240808 (date) — Filing date
- 001-40925 (company) — SEC file number
- 828 WINTER STREET (location) — Business and mail address
- WALTHAM (location) — City for business and mail address
- MA (location) — State for business and mail address
- 02451 (location) — ZIP code for business and mail address
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20240630, meaning the filing covers the period ending June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on 20240808.
What is Xilio Therapeutics' Standard Industrial Classification code?
Xilio Therapeutics' Standard Industrial Classification is PHARMACEUTICAL PREPARATIONS [2834].
Where is Xilio Therapeutics located?
Xilio Therapeutics' business and mail address is 828 WINTER STREET, WALTHAM, MA 02451.
What is the SEC file number for Xilio Therapeutics?
The SEC file number for Xilio Therapeutics is 001-40925.
Filing Stats: 4,457 words · 18 min read · ~15 pages · Grade level 19.2 · Accepted 2024-08-08 07:51:00
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share XLO Nasdaq Global Select
Filing Documents
- xlo-20240630x10q.htm (10-Q) — 1871KB
- xlo-20240630xex10d2.htm (EX-10.2) — 81KB
- xlo-20240630xex31d1.htm (EX-31.1) — 13KB
- xlo-20240630xex31d2.htm (EX-31.2) — 13KB
- xlo-20240630xex32d1.htm (EX-32.1) — 8KB
- 0001558370-24-011471.txt ( ) — 6315KB
- xlo-20240630.xsd (EX-101.SCH) — 42KB
- xlo-20240630_cal.xml (EX-101.CAL) — 36KB
- xlo-20240630_def.xml (EX-101.DEF) — 204KB
- xlo-20240630_lab.xml (EX-101.LAB) — 372KB
- xlo-20240630_pre.xml (EX-101.PRE) — 322KB
- xlo-20240630x10q_htm.xml (XML) — 732KB
Financial Statements (unaudited)
Financial Statements (unaudited) 7 Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 7 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2024 and 2023 8 Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2024 and 2023 9 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 11 Notes to Condensed Consolidated Financial Statements 12 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 38 Item 4.
Controls and Procedures
Controls and Procedures 38 Part II Other Information 39 Item 1A.
Risk Factors
Risk Factors 39 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 107 Item 5. Other Information 107 Item 6. Exhibits 109
Signatures
Signatures 6 Table of Contents
—FINANCIAL INFORMATION
PART I—FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements XILIO THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share data) (Unaudited) June 30, December 31, 2024 2023 ASSETS Current assets Cash and cash equivalents $ 74,949 $ 44,704 Prepaid expenses and other current assets 3,059 3,423 Total current assets 78,008 48,127 Restricted cash 1,769 1,587 Property and equipment, net 5,137 5,942 Operating lease right-of-use asset 4,867 5,125 Other non-current assets 92 145 Total assets $ 89,873 $ 60,926 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 1,264 $ 1,050 Accrued expenses 9,737 10,497 Deferred revenue, current portion 26,517 — Operating lease liability, current portion 1,116 1,047 Note payable, current portion — 3,315 Other current liabilities 7 48 Total current liabilities 38,641 15,957 Deferred revenue, net of current portion 10,250 — Operating lease liability, net of current portion 7,566 8,142 Total liabilities 56,457 24,099 Commitments and contingencies (Note 7) Stockholders' equity Preferred stock, $ 0.0001 par value; 5,000,000 shares authorized, no shares issued or outstanding — — Common stock, $ 0.0001 par value; 200,000,000 shares authorized at June 30, 2024 and December 31, 2023; 43,951,922 shares issued and outstanding at June 30, 2024; 27,613,263 shares issued and 27,607,646 shares outstanding at December 31, 2023 4 3 Additional paid-in capital 390,052 362,336 Accumulated deficit ( 356,640 ) ( 325,512 ) Total stockholders' equity 33,416 36,827 Total liabilities and stockholders' equity $ 89,873 $ 60,926 The accompanying notes are an integral part of these condensed consolidated financial statements. 7 Table of Contents XILIO THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share data